Company / PP&E (Net)
Rein Therapeutics, Inc. PP&E (Net) History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.0K
FY2024
5-year range
$1.0K / $128.0K
FY2020-FY2024
Trend
-94.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has declined for 3 consecutive years, from $128,000 in FY2021 to $1,000 in FY2024.
Based on SEC 10-K filings.
$1,000 in FY2024 with a 5-year CAGR of -67.9%.
Declined from $70,000 to $1,000 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -80.2%
- 5-Year CAGR
- -67.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Rein Therapeutics, Inc.'s pp&e (net) has declined for 3 consecutive years.
- 5-year CAGR of -67.9%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 94.7% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $1.0K | -94.7% |
| FY2023 | $19.0K | -72.9% |
| FY2022 | $70.0K | -45.3% |
| FY2021 | $128.0K | +753.3% |
| FY2020 | $15.0K | -94.9% |
| FY2019 | $295.0K | -96.0% |
| FY2018 | $7.3M | +4633.8% |
| FY2017 | $154.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026